Clinical Trials · NCT07302802

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Phase
N/A
Recruitment status
Recruiting
Sponsor
Prof. Dr. Martin Wabitsch
Enrollment
70
Start date
Dec 2025
Locations
7 sites, 5 countries
Primary endpoint
Proportion of participants achieving ≥10% BMI reduction from baseline (week 0) to week 68.
View Semaglutide compound reference